Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/Ritonavir Effect on Rosuvastatin PK
NCT05898672Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity and Maximum Observed Concentration. Started Jun 2023; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05898672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898672.